This Will Be Johnson and Johnson’s Stock Price in 2027

6 hours ago 4

Vandita Jadeja

Tue, May 19, 2026 astatine 9:21 AM CDT 4 min read

Quick Read

Johnson & Johnson (JNJ) reported Q1 gross of $24.06B, up 9.9% twelvemonth implicit year, with adjusted EPS of $2.70 beating statement for the 4th consecutive quarter, portion oncology drugs CARVYKTI jumped 62.1% to $597M and RYBREVANT surged 82.7%, offsetting a 59.7% diminution successful STELARA from biosimilar competition.
Johnson & Johnson’s oncology pipeline spot and planned separation of its Orthopaedics concern are creating a way to double-digit maturation by decade-end, offsetting bequest cause erosion and supporting a 90% assurance bargain standing with a $252.01 terms people implying 9.37% upside.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Johnson & Johnson wasn't 1 of them. Get them present FREE.

Johnson & Johnson (NYSE:JNJ) closed the astir caller league astatine $230.42, up 2.58% connected the week arsenic buyers rotated backmost into antiaircraft healthcare names. Our 24/7 Wall St. terms people for Johnson & Johnson is $252.01 implicit the adjacent 12 months, implying 9.37% upside. The proposal is buy, and our assurance level is 90%, the precocious extremity of our scale.

24/7 Wall St. Price Target Summary

Metric

Value

Current Price	$230.42
24/7 Wall St. Price Target	$252.01
Upside	9.37%
Recommendation	BUY
Confidence Level	90%

A Defensive Compounder Riding Oncology Strength

JNJ has been 1 of the strongest performers successful large-cap pharma implicit the past year, rising 59.53% implicit 12 months and 11.93% twelvemonth to date. The banal pulled backmost 3.17% implicit the past period aft the Q1 net report, but the 14-day RSI has rebounded from oversold territory to 51.98, signaling renewed buying interest.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Johnson & Johnson wasn't 1 of them. Get them present FREE.

Q1 2026 was a cleanable beat. Revenue of $24.06 cardinal grew 9.9% twelvemonth implicit year, and adjusted EPS of $2.70 extended the statement bushed streak to 4 consecutive quarters. Innovative Medicine grew 11.2% with DARZALEX astatine $3.96 cardinal and TREMFYA up 68.3%, much than absorbing a 59.7% STELARA diminution from biosimilar competition. Management raised full-year gross guidance to $100.3B to $101.3B and adjusted EPS to $11.45 to $11.65.

The Case for $266+

The bull script takes JNJ to $265.94, a 15.41% return. The operator is oncology. CARVYKTI grew 62.1% to $597 million, RYBREVANT/LAZCLUZE jumped 82.7%, and the caller TECVAYLI positive DARZALEX FASPRO operation opens a second-line myeloma indication.

Add the ICOTYDE psoriasis launch, VARIPULSE Pro successful Europe, and a $1 cardinal Pennsylvania compartment therapy facility, and management's framing of a way to double-digit maturation by decade-end looks credible. Insider buying reinforces this: R&D main John Reed acquired 25,255 shares connected May 1, 2026. The planned Orthopaedics concern separation could unlock a sum-of-the-parts rerating northbound of $270.

Read Entire Article